Thursday, June 11, 2026
🇺🇸 FDA

pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp clinical programs — 50 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

MSD Merck Sharp projects

50 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.

MSD Merck Sharp has 50 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

50 programs

Clinical programs

Page 1 of 2

  1. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  2. A Single-Ascending-Dose Study of MK6916 in Healthy Participants

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  3. A clinical study of MK-0472 in people with solid tumors (MK-0472-001)

    Merck Sharp and Dohme

    Malignant Neoplasm - Solid Tumors

    phase 1 other active

    1 trial

  4. A clinical study of MK-1289 in healthy adult men (MK-1289-001)

    Merck Sharp and Dohme

    COVID-19 Infection

    phase 1 other active

    1 trial

  5. A clinical study of MK-1403 in healthy men (MK-1403-004)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  6. A clinical study of MK-1403 in healthy people (MK-1403-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  7. A clinical study of MK-2420 in healthy men (MK-2420-003)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  8. A clinical study of MK-2420 in healthy people (MK-2420-002)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  9. A clinical study of MK-2828 in healthy people (MK-2828-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  10. A clinical study of MK-2828 in healthy people (MK-2828-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  11. A clinical study of MK-3214 in healthy people (MK-3214-001)

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  12. A clinical study of MK-3508 in healthy people (MK-3508-006)

    Merck Sharp and Dohme

    Respiratory syncytial virus infection

    phase 1 other active

    1 trial

  13. A clinical study of MK-4082 in healthy people (MK-4082-001)

    Merck Sharp and Dohme

    Weight management

    phase 1 other active

    1 trial

  14. A clinical study of MK-4646 in healthy people (MK-4646-002)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  15. A clinical study of MK-4646 in people with HIV (MK-4646-003)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  16. A clinical study of MK-5661 and placebo in healthy people (MK-5661-006)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  17. A clinical study of MK-5661 in healthy people (MK-5661-007)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  18. A clinical study of MK-6050 in healthy people (MK-6050-001)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  19. A clinical study of MK-6916 and placebo in healthy people (MK-6916-003)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  20. A clinical study of MK-6916 in healthy people (MK-6916-002)

    Merck Sharp and Dohme

    Acute and Chronic Pain

    phase 1 other active

    1 trial

  21. A clinical study of MK-6916 in healthy people (MK-6916-006)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  22. A clinical study of MK-7228 in healthy men (MK-7228-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  23. A clinical study of the V540A vaccine in healthy adults (V540A-001)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  24. A clinical study of the V540C vaccine in healthy adults (V540C-003)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  25. A clinical trial of MK-1824 in healthy participants (MK-1824-001)

    Merck Sharp and Dohme

    Heart failure with preserved ejection fraction

    phase 1 other active

    1 trial

  26. A clinical trial of MK-4605 in healthy participants (MK-4605-001)

    Merck Sharp and Dohme

    Dementia

    phase 1 other active

    1 trial

  27. A clinical trial of MK-6050 in healthy participants (MK-6050-002)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  28. A clinical trial of MK-6916 in healthy participants (MK-6916-010)

    Merck Sharp and Dohme

    Acute and Chronic pain

    phase 1 other active

    1 trial

  29. A clinical trial of MK-7228 in adults (MK-7228-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  30. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  31. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  32. Effect of Renal Impairment on Enpatoran Pharmacokinetics

    Merck Sharp and Dohme

    Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

    phase 1 other active

    1 trial

  33. M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 1 other active

    1 trial

  34. MK-1045-004

    Merck Sharp and Dohme

    Systemic lupus erythematosus, Rheumatoid arthritis

    phase 1 other active

    1 trial

  35. MK-2420 SAD Study

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  36. MK-3214-002

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  37. MK-4318 CIDF Target Engagement Study

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  38. MK-4646 Single Ascending Dose Study and DDI in Healthy Participants

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  39. MK-4830-001

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  40. MK-7091 Formulations Study in Healthy Adult Participants

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 1 other active

    1 trial

  41. MK-7480 Multiple Ascending Dose Study in Healthy Participants

    Merck Sharp and Dohme

    Non-alcoholic steatohepatitis

    phase 1 other active

    1 trial

  42. MK-8294-001

    Merck Sharp and Dohme

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    phase 1 other active

    1 trial

  43. MS100070_0087

    Merck Sharp and Dohme

    Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  44. MS200569_0065

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  45. MS201924_0001

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  46. MS201924_0003

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  47. MS202359_0025

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  48. MS202650_0001

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does MSD Merck Sharp have?

50 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.